A California man has filed a new Gadolinium suit in the Northern District of California. According to the lawsuit, a medical professional injected him with the dye during an MRI. However, he suffered brain injuries after receiving the injection.
Gadolinium is a chemical element carrying the atomic number 64 and the atomic symbol Gd. Belonging to a group of elements in the periodic table called Lanthanides, the chemical is a rare earth element typically used in microwave applications, color TV tubes, synthetic gemstones, compact discs, and computer memory. The medical community uses this chemical element as an injectable contrast agent when patients undergo magnetic resonance Imaging (MRI) and magnetic resonance angiography (MRA) scans. Research has found that this chemical element is a toxic metal and any amount that remains in the brain and other parts of the body has the potential to have a harmful effect. The long-term effects of gadolinium deposition are still unknown as research is ongoing.
Medical professionals told the California man that gadolinium was safe. However, the dye from Optimark and Multihance injections remained in his body for years after his MRI. Before injection, the man had normal kidney function. However, the dye ravaged his organs including his brain. In September 2017, a urine test still showed the toxic dye in his body. He had other symptoms which included severe pain, skin hardening, burning sensations, difficulty walking, cognitive issues, loss of balance, and sensations of tightness in his skin.
Manufacturers Failed to Warn Consumers
In the Gadolinium suit, the plaintiff says that the manufacturers of gadolinium did not warn consumers that the dye can build up in the body. If they did, then the plaintiff would never have been injected. In fact, the manufacturers knew that gadolinium could cross the blood-brain barrier and could negatively affect the brain. Also, they stated that the body expels the chemical, but research now shows that isn’t always the case.
In fact, a 2016 article in Invest Radiology, notes animal specimens used in clinical trials in 1984 still have gadolinium deposits. In 1998, there was the first main study linking gadolinium deposits in humans with abnormal kidney function. Then, in 2004, researchers linked deposits in humans with normal kidney function.
Free Case Evaluation
A gadolinium lawsuit may be an option for patients suffering from gadolinium retention and related complications. Gadolinium, used in dyes to increase the clarity of MRI and MRA scans, can create chemical element retention in the body, Therefore, this increases the risk of gadolinium deposition disease and nephrogenic systemic fibrosis. These conditions are accompanied with symptoms that include severe physical pain and cognitive difficulties. Affected patients and their loved ones may be able to file a lawsuit and recover damages.
Therefore, for more information, contact The Michael Brady Lynch Firm. We offer free, confidential, no obligation consultations. We have over 20 years experience helping consumers injured by unsafe products manufactured by large companies.